Ganga Pharma. (539680)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive sales growth of 4.58% shows some top-line traction
• Stock near 52-week high indicates market interest or momentum
• Low absolute market cap of ₹13 crore could allow high growth if business turns
• No reported debt in the data, though incomplete

Concerns

• P/E of 88.62 with zero profit growth implies extreme overvaluation
• ROCE of just 3.18% indicates poor capital efficiency
• Latest quarter net profit is ₹0 crore — no actual earnings generation
• Piotroski F-Score of 4/9 points to weak fundamental health

AI Analysis

Let's look at Ganga Pharma with the same lens I'd use for any business: what is the return on capital, how durable is the franchise, and what am I paying for earnings? The first thing that jumps out is the valuation: ₹24.67 per share for a market cap of ₹13 crore, against a P/E of 88.62. That means the market is paying nearly 89 times trailing earnings for a company whose net profit is basically flat — zero growth. The latest quarter tells the story: sales of just ₹1 crore and net profit of ₹0 crore. That's not a business compounding wealth; it's a micro-cap struggling to generate meaningful returns. ROCE is only 3.18%, far below what I'd demand even for a fixed deposit, let alone an equity investment with real risk. Sales growth of 4.58% is anemic, and the Piotroski score of 4/9 suggests weak financial health — no sign of improving profitability, leverage, or efficiency. There is no dividend, so the only possible return is price appreciation, but with such a tiny earnings base and no clear catalyst, that's speculative. I cannot calculate book value or return on equity because the data is missing — and in my experience, when information is absent, it's rarely because the numbers are flattering. The 52-week range shows the stock has tripled from ₹9.35 to ₹24.67, but that looks more like a momentum move than a fundamental re-rating. As Graham would say, price is what you pay, value is what you get. Here, the value is impossible to justify. This is a slow grower at best, and at this price, it's dangerously close to a speculation. I'd rather watch from the sidelines until the business proves it can earn a real return on capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer